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We provide a comprehensive review of the role of β-hydroxybutyrate (β-OHB), its linear
polymer poly-β-hydroxybutyrate (PHB), and inorganic polyphosphate (polyP) in mammalian
health and disease. β-OHB is a metabolic intermediate that constitutes 70% of ketone
bodies produced during ketosis. Although ketosis has been generally considered as an
unfavorable pathological state (e.g., diabetic ketoacidosis in type-1 diabetes mellitus), it
has been suggested that induction of mild hyperketonemia may have certain therapeutic
benefits. β-OHB is synthesized in the liver from acetyl-CoA by β-OHB dehydrogenase and
can be used as alternative energy source. Elevated levels of PHB are associated with
pathological states. In humans, short-chain, complexed PHB (cPHB) is found in a wide
variety of tissues and in atherosclerotic plaques. Plasma cPHB concentrations correlate
strongly with atherogenic lipid profiles, and PHB tissue levels are elevated in type-1
diabetic animals. However, little is known about mechanisms of PHB action especially
in the heart. In contrast to β-OHB, PHB is a water-insoluble, amphiphilic polymer that
has high intrinsic viscosity and salt-solvating properties. cPHB can form non-specific ion
channels in planar lipid bilayers and liposomes. PHB can form complexes with polyP and
Ca2+ which increases membrane permeability. The biological roles played by polyP, a
ubiquitous phosphate polymer with ATP-like bonds, have been most extensively studied
in prokaryotes, however polyP has recently been linked to a variety of functions in
mammalian cells, including blood coagulation, regulation of enzyme activity in cancer
cells, cell proliferation, apoptosis and mitochondrial ion transport and energy metabolism.
Recent evidence suggests that polyP is a potent activator of the mitochondrial permeability
transition pore in cardiomyocytes and may represent a hitherto unrecognized key structural
and functional component of the mitochondrial membrane system.
Keywords: inorganic polyphosphate, β-hydroxybutyrate, poly-β-hydroxybutyrate, cardiovascular disease, heart
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WHAT IS β-HYDROXYBUTYRATE?
β-Hydroxybutyrate (β-OHB; also known as 3-hydroxybutyric
acid) is a metabolic intermediate that constitutes∼70% of ketone
bodies produced in liver mitochondria mainly from the oxidation
of fatty acids released from adipose tissue (Persson, 1970). The
term “ketone bodies” refers to three molecules: (1) β-OHB, (2)
its dehydrogenated counterpart acetoacetate (AcAc), and (3) the
decarboxylated AcAc, acetone (Figure 1). Acetone, produced in
smaller quantities than the other ketone bodies, is exhaled and
essentially is unmeasurable in healthy individual (Laffel, 1999;
Abbreviations: AcAc, acetoacetate; AF, atrial fibrillation; BDH, D-β-
hydroxybutyrate dehydrogenase; β-OHB, β-hydroxybutyrate; cPHB, complexed
poly-β-hydroxybutyrate; FFAR3, free fatty acid receptor 3; FOXO3a, Forkhead
box O3a; GPCRs, G-protein-coupled receptors; IDL, intermediate density
lipoproteins; HDACs, class I histone deacetylases; HF, heart failure; HMG-CoA,
β-hydroxy-β-methylglutaryl-CoA; LCKD, low carbohydrate ketogenic diet; LDL,
low density lipoproteins; LFI, low flow ischemia; PHB, poly-β-hydroxybutyrate;
polyP, inorganic polyphosphate; SCOT, succinyl-CoA:3-oxoacid-CoA transferase;
TCA, tricarboxylic acid; VLDL, very low density lipoproteins.
Cahill and Veech, 2003). AcAc and β-OHB are transported by
blood to the extrahepatic tissues, where they are oxidized via the
tricarboxylic acid (TCA) cycle to provide the energy required by
tissues such as skeletal and heart muscle and the renal cortex
(Figure 2). In the normal adult heart, mitochondrial oxidative
phosphorylation provides more than 95% of the ATP gener-
ated for its mechanical, electrical and homeostatic needs. Fatty
acid oxidation accounts for up to 70% of the ATP produced
by the heart, with metabolism of glucose, lactate, amino acids
and ketone bodies supplying the rest (reviewed in Lopaschuk
et al., 2010; Cotter et al., 2013). However, ketone body contri-
bution to the overall energy metabolism in the heart and other
extrahepatic tissues increases significantly after prolonged exer-
cise, during fasting, adherence to low carbohydrate ketogenic
diet (LCKD) and in the neonatal period (Veech et al., 2001;
Veech, 2004). In these physiological situations, the concentra-
tion of circulating blood β-OHB rises from ∼0.1mM observed
in normal fed state to ∼1mM after few hours of fasting, and
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up to 5–7mM after prolonged starvation (Cahill, 1970; Robinson
and Williamson, 1980; Laffel, 1999; Cahill and Veech, 2003). If
the release of free fatty acids from adipose tissue exceeds the
capacity of tissue to metabolize them, as occurs during insulin
deficiency of type I diabetes or less commonly in the insulin-
resistant of type II diabetes, severe and potentially fatal diabetic
ketoacidosis can occur where blood β-OHB levels can reach up to
25mM (Lebovitz, 1995; Cahill and Veech, 2003). Mild elevation
of blood ketone bodies also occurs during the process of normal
aging (Sengupta et al., 2010) and during congestive heart fail-
ure (HF) (Kupari et al., 1995; Lommi et al., 1996, 1997) however
it remains unclear whether this elevation represents an adaptive
mechanism required to maintain cell metabolism or actually con-
tributes to the progression of disease. Induction of mild states
of hyperketonemia may have certain therapeutic benefits (Veech
et al., 2001; Veech, 2004; Clarke et al., 2012b). Ketone body oxi-
dation is especially critical in the brain which cannot utilize fatty
acids for energy (free fatty acids do not cross the blood-brain
barrier) when blood glucose levels become compromised. In this
case, ketone bodies provide the brain with an alternative source of
energy, amounting to nearly 75% of the brain’s energy needs dur-
ing periods of prolonged fasting and starvation (Owen et al., 1967;
Cahill, 2006). It has been known formany years that children with
multidrug-resistant refractory epilepsy improve dramatically on a
strict LCKD (Veech, 2004), and recent data indicate that β-OHB
supplementation protects neurons in models of Alzheimer and
Parkinson’s disease (Kashiwaya et al., 2000; Tieu et al., 2003; Reger
et al., 2004). The laboratory of Veech (Kashiwaya et al., 1994; Sato
et al., 1995) was first to report that addition of 4mM β-OHB
to the working perfused rat heart induced an increase in work
output but a significant decrease in oxygen consumption. The
data demonstrated that the increased efficiency was the result of
the widening mitochondrial substrate ratio of NADH and NAD+
between complex 1 and complex 2 of the mitochondrial respira-
tory chain. The net effect is a greater potential for ATP production
making β-OHB the most efficient fuel in the heart.
Evolutionary, metabolism of ketone bodies is conserved
among eukarya, bacteria, and archaea (Reusch, 1992; Aneja et al.,
2002; Cahill, 2006). Most bacteria use poly-β-hydroxybutyrate
(PHB, Figure 1), a polymerized form of β-OHB, as an energy
store (Anderson and Dawes, 1990; Reusch, 1992, 2012). PHB con-
sists up to 90% of dry weight in some protozoans. Even archaea
use it for energy storage, which suggests it has been around for
well over 2–3 billion years. It is possible that its selection was
aided by the periods of low environmental oxygen that occurred
during the Archaean, Proterozoic, and Palaeozoic eras (Cahill,
2006). PHB is stored as several large granules in the cytoplasm
(Anderson and Dawes, 1990; Reusch, 2012), therefore having very
little osmotic effect which is in contrast to two other funda-
mental archaeal energy stores, inorganic polyphosphate (polyP)
(Kornberg, 1995; Kornberg et al., 1999) and various polysaccha-
rides (Dawes and Senior, 1973). It has been believed that both
polyP and PHB remained only in the prokaryotes, however the
raising number of studies demonstrated the presence of both
polyP and PHB in mammalian cells, and their important phys-
iological roles. Since only small amounts of PHB and polyP are
detected in mammalian cells, it is thought that they do not serve
as an energy store (Kulaev et al., 2004) but rather participate
in cell signaling and proliferation, regulation of mitochondrial
function, channel activity, blood coagulation and inflammation,
and bone tissue development. This review discusses the roles
of β-OHB, PHB, and inorganic polyP with specific focus on
cardiovascular health and disease.
WHAT IS POLY-β-HYDROXYBUTYRATE (PHB)?
PHB (also known as Poly-(R)-3-hydroxybutyrate) is a biopoly-
mer consisting of linear chains of β-OHB (Figure 1). Three types
of PHB with different numbers of β-OHB units and with differ-
ent functions have been discovered: (i) high molecular weight
storage PHB consists of 10,000 to >1,000,000 β-OHB residues
(storage PHB), (ii) low molecular weight PHB with medium–
chain length consisting of 100–300 residues (oligo-PHB), and (iii)
short-chain conjugated PHB (cPHB) in which low numbers of β-
OHB residues (≤30) are covalently linked to proteins (see Reusch,
1992, 2012, 2013 for comprehensive reviews). Storage PHB was
first discovered in granular inclusion bodies (termed carbono-
somes) within the cytoplasm of Bacillus megaterium in 1925, and
later in a wide variety of archaea and eubacteria, principally those
that inhabit soil and water ecosystems (Nuti et al., 1972; Anderson
and Dawes, 1990; Poli et al., 2011). PHB is produced by these
prokaryotes when carbon sources are freely available but other
nutrients are limited, thus PHB is considered to serve as a carbon
and energy store in these organisms. PHB located within car-
bonosomes are covered by a layer of lipids and proteins, which
include enzymes involved in PHB synthesis and degradation
(Potter and Steinbuchel, 2005; Rehm, 2006; Jendrossek, 2009),
have attained considerable commercial importance as ingredi-
ents of biodegradable plastics and high-technology materials in
the medical field (Wu et al., 2009). PHB of medium-chain length
was first discovered in the cytoplasmic membranes of genetically-
competent bacteria Azotobacter vinelandii, Bacillus subtilis and
Haemophilus influenzae by Reusch and Sadoff (1983) and later in
Escherichia coli (E. Coli) (Reusch and Sadoff, 1983; Reusch et al.,
1986). Interestingly, that H. influenzae and E. coli do not accu-
mulate PHB granules. Medium-chain PHB, like storage PHB, is
insoluble in water and soluble in chloroform, and non-covalently
associated with other molecules. In 1989, medium-chain length
PHB was recovered from membranes, mitochondria and micro-
somes of eukaryotes (Reusch, 1989), and in 1992 from very
low density and low density lipoproteins (VLDL and LDL) of
human plasma (Reusch et al., 1992). The identity of medium-
chain length PHB in representative prokaryotic and eukaryotic
organisms was revealed by 1H-NMR spectroscopy by Reusch
(1992) and confirmed by Seebach et al. (1994). Medium-chain
length PHB has been found associated with inorganic polyP in
non-covalent complexes that are postulated to play a role in trans-
bilayer transport of cations (Reusch and Sadoff, 1988; Reusch
et al., 1995; Das et al., 1997) and deoxyribonucleic acids (Castuma
et al., 1995; Huang and Reusch, 1995; Reusch, 2000). Huang
and Reusch (1996) discovered short-chain PHB (≤10 residues)
covalently bound to specific proteins in the membranes and the
cytoplasm of E. coli. It is generally thought to consist of ≤30
residues but this remains unclear due to the lability of the ester
bond and the paucity of samples examined to date. Unlike storage
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FIGURE 1 | Formation of ketone bodies in liver mitochondria. The
synthesis of β-OHB begins with the condensation of two molecules of
acetyl-CoA to form acetoacetyl-CoA, the parent of the three ketone bodies, by
a ketothiolase enzyme. In prokaryotes, this intermediate is subsequently
reduced with NADPH to hydroxybutyryl-CoA by acetoacetyl-CoA reductase,
and hydroxybutyryl-CoA may then be polymerized to form PHB by the enzyme
PHB synthase. In eukaryotes, 3-hydroxy-3-methylglutaryl-CoA synthase (HMG
synthase) catalyzes the condensation of acetoacetyl-CoA with a third
acetyl-CoA to form β-hydroxy-β-methylglutaryl-CoA (HMG-CoA). The enzyme
HMG-CoA lyase then catalyzes the decomposition of HMG-CoA to form
acetoacetate and acetyl-CoA, and acetoacetate is further reduced with NADH
by phosphatidylcholine-dependent mitochondrial D-β-hydroxybutyrate
dehydrogenase to form β-OHB (Lehninger et al., 1960; Marks et al., 1992).
Acetoacetate is also non-enzymatically decarboxylated to acetone.
PHB that is segregated within cytoplasmic granules and medium-
chain PHB that is “dissolved” in lipid environments, cPHB has
been found in all cell compartments of prokaryotes and eukary-
otes and in intracellular fluids (Reusch et al., 1997, 2002, 2003;
Reusch, 1999; Norris et al., 2009). Indeed, the majority of PHB
in cells that do not accumulate long-chain storage PHB is cPHB.
It has been postulated that cPHB forms supra-molecular com-
plexes with proteins via covalent bonds andmultiple hydrophobic
interaction sites (Reusch, 1989, 1999; Seebach et al., 1994). The
physical properties of cPHB and large size of the polyester may
have substantial structural and functional impacts on the protein.
The high-energy C-terminal CoA-ester group, derived from PHB
metabolic precursors, presumably acts as a cofactor for the enzy-
matic reaction in which a covalent bond to the protein is formed
(Zhang et al., 2011). This covalent attachment of cPHB is known
as PHBylation (Cao et al., 2013) and plays roles in protein fold-
ing, protein sorting, or retention of inorganic polyP (Xian et al.,
2007; Negoda et al., 2010; Cao et al., 2013). In eukaryotes, cPHB
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was found to be bound to the Ca2+-ATPase pump of human
erythrocyte membranes (Reusch et al., 1997), which is the sole
transporter of Ca2+ in red blood cells. Interestingly, inorganic
polyP was also present in this complex, and it was suggested that
Ca2+-ATPase is a supra-molecular structure consisting of pro-
tein, cPHB, and polyP. Solvation of polyP by PHB could allow
this polyanion to penetrate into the bilayer portion of Ca2+-
ATPase, and possibly mediate Ca2+ transfer (Reusch et al., 1997).
Recently, it has been found that a member of the transient recep-
tor potential channel family of the melastatin subgroup, TRPM8,
which is a major sensor for cold temperatures in the periph-
eral nervous system, is significantly modified by both cPHB and
polyP (Zakharian et al., 2009, 2010; Cao et al., 2013). Moreover,
it has been shown that cPHB/polyP complexes isolated from
rat liver mitochondria can form voltage-dependent ion channels
with multiple conductance states when incorporated in planar
lipid bilayers (Pavlov et al., 2005b). The characteristics of this
channel activity closely resembled the behavior of the mitochon-
drial permeability transition pore (mPTP) channel observed in
patch-clamp experiments in nativemitoplasts (see below formore
information). The ubiquitous occurrence of the medium-chain
and short-chain polyester (Reusch and Sadoff, 1988; Reusch,
1989, 1992; Reusch et al., 1992, 2003; Seebach et al., 1994; Norris
et al., 2009; Zakharian et al., 2009, 2010; Elustondo et al., 2012),
suggests that PHB, like polyisoprenoids, polypeptides, polysac-
charides, and polynucleotides, is a fundamental constituent of
biological cells.
MECHANISMS OF β-OHB/PHB PRODUCTION AND
UTILIZATION
Ketone body metabolism includes both ketogenesis and ketoly-
sis (see McGarry and Foster, 1980; Robinson and Williamson,
1980; Cotter et al., 2013 for comprehensive reviews). Ketogenesis
is the process by which fatty acids are transformed into AcAc and
β-OHB (Figures 1, 2). This process takes place in the mitochon-
dria of liver cells and can occur in response to unavailability of
blood glucose (Robinson and Williamson, 1980). The produc-
tion of ketone bodies is then initiated to make available energy
primarily from fatty acids. Fatty acids are enzymatically bro-
ken down in β-oxidation to form acetyl-CoA. Under normal
conditions, acetyl-CoA is further oxidized and its energy trans-
ferred as electrons to NADH and FADH2 in the TCA cycle, and
FIGURE 2 | Ketone body utilization in mitochondria of extrahepatic
organs. When ketone bodies are delivered to the peripheral organs, β-OHB is
oxidized back to acetoacetate by the mitochondrial BDH1. Then, acetoacetate
gets converted to acetoacetyl-CoA by the mitochondrial enzyme succinyl-CoA:
3-oxoacid-CoA transferase (SCOT). The succinyl-CoA:3-oxoacid-CoA
transferase uses succinyl-CoA as the CoA donor, forming succinate and
acetoacetyl-CoA. This reaction bypasses the succinyl-CoA synthetase step of
the TCA cycle, although it does not alter the amount of carbon in the cycle.
Next, mitochondrial thiolase cleaves the acetoacetyl-CoA into two molecules
of acetyl-CoA, which can generate energy by entering the TCA cycle pathway.
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further to ATP in the mitochondrial respiratory chain (Figure 2).
However, if the amounts of acetyl-CoA generated in fatty acid
β-oxidation challenge the processing capacity of the TCA cycle
or if activity in the TCA cycle is low due to low amounts of inter-
mediates such as oxaloacetate, acetyl-CoA is then used instead in
biosynthesis of ketone bodies via acetoacyl-CoA and β-hydroxy-
β-methylglutaryl-CoA (HMG-CoA). Deaminated amino acids
that are ketogenic, such as leucine, also feed the TCA cycle, form-
ing AcAc and acetyl-CoA, and thereby generate up to 4% of circu-
lating ketones (Merritt et al., 2011). Glucose metabolism accounts
for ∼1% of circulating ketones in states of low-carbohydrate
intake because pyruvate predominantly enters the hepatic TCA
cycle via carboxylation to oxaloacetate or malate rather than
decarboxylation (to acetyl-CoA) (Magnusson et al., 1991; Merritt
et al., 2011; Jeoung et al., 2012).
The synthesis of β-OHB begins with (i) the condensation
of two molecules of acetyl-CoA to form acetoacetyl-CoA by
a ketothiolase enzyme; this is simply the reversal of the last
step of β–oxidation (Figure 1). In prokaryotes, this intermedi-
ate is subsequently reduced with NADPH to hydroxybutyryl-
CoA by acetoacetyl-CoA reductase, and hydroxybutyryl-CoAmay
then be polymerized to form PHB by the enzyme PHB syn-
thase (Anderson and Dawes, 1990; Poli et al., 2011; Reusch,
2013). (ii) In eukaryotes, 3-hydroxy-3-methylglutaryl-CoA syn-
thase 2 (HMG synthase 2) catalyzes the condensation of
acetoacetyl-CoA with a third acetyl-CoA to form HMG-CoA
(Bahnson, 2004). HMG synthase 2 is exclusively present in liver
mitochondria. HMG synthase 1 is located in cytosol and asso-
ciated with cholesterol biosynthesis. (iii) The enzyme HMG-
CoA lyase then catalyzes the decomposition of HMG-CoA to
form AcAc and acetyl-CoA, and AcAc is further reduced with
NADH by phosphatidylcholine-dependent mitochondrial D-β-
hydroxybutyrate dehydrogenase to form β-OHB (Lehninger et al.,
1960; Marks et al., 1992). AcAc is also non-enzymatically decar-
boxylated to acetone. The ratio of β-OHB to AcAc depends on
the NADH/NAD+ ratio inside mitochondria; if NADH concen-
tration is high, the liver releases a higher proportion of β-OHB.
Enzymes that polymerize β-OHB or its CoA ester have not yet
been identified in eukaryotes (Reusch, 2013). Ketone bodies are
released by the liver via solute carrier 16A (SLC16A) family mem-
bers 1, 6, and 7 and circulate to extrahepatic tissues where they
primarily undergo terminal oxidation (Halestrap, 2012; Halestrap
and Wilson, 2012; Hugo et al., 2012).
When ketone bodies are delivered to the peripheral organs,
β-OHB is oxidized back to AcAc by the mitochondrial D-β-
hydroxybutyrate dehydrogenase (Figure 2). The utilization of
ketone bodies requires an enzyme not present in the ketone body
biosynthetic pathway, succinyl-CoA:3-oxoacid-CoA transferase
(also known as SCOT), which converts AcAc to acetoacetyl-CoA.
This enzyme is not present in liver, and therefore the liver lacks
the ability to utilize ketones. The SCOT uses succinyl-CoA in the
TCA cycle as the CoA donor, forming succinate and acetoacetyl-
CoA. This reaction bypasses the succinyl-CoA synthetase step of
the TCA cycle, although it does not alter the amount of carbon
in the cycle. Next, mitochondrial thiolase cleaves the acetoacetyl-
CoA into two molecules of acetyl-CoA, which can generate
energy by entering the TCA cycle pathway (Figure 2). This also
implies that TCA cycle must be running to allow ketone body
utilization.
FEEDBACK REGULATION OF β-OHB SYNTHESIS VIA β-OHB
RECEPTORS
β-OHB is a ligand for at least two G-protein-coupled receptors
(GPCRs) that bind short-chain fatty acids. HCAR2 (hydroxycar-
boxylic acid receptor 2; also known as PUMA-G or Gpr109), a
Gi/o-coupled GPCR, first identified as a nicotinic acid receptor
(Tunaru et al., 2003), was recently shown to bind and be acti-
vated by β-OHB (Taggart et al., 2005). It has been demonstrated
that fatty acid derived β-OHB specifically activates HCAR2 recep-
tors within physiologically relevant β-OHB concentrations (Ki =
0.7mM) (Taggart et al., 2005), typically observed in serum during
short-term fasting. Like nicotinic acid, β-OHB reduces lipoly-
sis in mouse adipocytes (with EC50 ∼2mM) possibly creating a
negative feedback mechanism to regulate availability of the fatty
acid precursors of ketone body metabolism (Taggart et al., 2005;
Offermanns et al., 2011). Indeed, in a study of the serum free
fatty acids-lowering effect of β-OHB infused in humans, Senior
and Loridan (1968) proposed that during starvation ketone bod-
ies exert “a fine regulatory adjustment” of their own synthesis by
inhibiting adipocyte lipolysis. β-OHB also binds to and antago-
nizes the free fatty acid receptor 3 (FFAR3, also known as GPR41),
another Gi/o protein-coupled receptor that is present in sympa-
thetic ganglions, thereby suppressing sympathetic activity and, in
turn, overall metabolic rate in mice (Kimura et al., 2011; Won
et al., 2013). Thus, through its actions on HCAR2 and FFAR3,
β-OHB may reduce lipolysis, reduce sympathetic tone, and lower
metabolic rate.
ROLE OF β-OHB IN CARDIOVASCULAR HEALTH AND
DISEASE
The rate of fatty acid oxidation in the normal healthy heart is a
function of the arterial free fatty acid concentration and the activ-
ities of the enzymes involved in fatty acid transport and oxidation
in the mitochondria, specifically carnitine-palmitoyl transferase I
(CPT-I) and the enzymes of the β-oxidation pathway (Lopaschuk
et al., 1994, 2010; Kunau et al., 1995). The heart readily oxidizes
ketone bodies (β-OHB and AcAc) in a concentration-dependent
manner at the expense of fatty acid oxidation (Lammerant et al.,
1985; Forsey et al., 1987; Stanley et al., 2003). β-OHB has the
ability to inhibit lipolysis (Hron et al., 1978), thereby inhibit-
ing the production of the free fatty acid that is implicated in
extendingmyocardial injury by elevating the expression of cardiac
mitochondrial uncoupling proteins and decreasing the expres-
sion of glucose transporter 4 (Murray et al., 2004; Opie, 2004).
In fact, the reduction of concentrations of free fatty acid con-
centration and the use of alternative substrates was proposed
for treatment of patients with HF (Murray et al., 2004). This
treatment would reduce mitochondrial uncoupling and restore
glucose uptake, thereby improving cardiac efficiency without a
fall in cardiac work. In addition, inhibition of fatty acid uti-
lization reduces oxygen demand of adjacent normal myocardial
tissue (Lammerant et al., 1985), preventing the extent of cellu-
lar damage (Liedtke et al., 1982). Thus, elevated concentrations
of β-OHB may prevent myocardial damage by preventing the
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formation of damaging intermediates as well as by serving as
an alternate energy source (Figure 2). Indeed, cardioprotective
effects have been observed using in vivo ischemia/reperfusion
approaches in rats subjected to starvation-induced ketosis, initi-
ated through prolonged fasting, and also via intravenous injection
of β-OHB immediately prior to ischemic injury, which conferred
a significant decrease in both infarct size and myocardial cell
death (Zou et al., 2002; Snorek et al., 2012). Moreover, it has
been demonstrated that LCKD enhances cardiac tolerance to
global ischemia (Al-Zaid et al., 2007). This study revealed a sig-
nificant decrease in the number of mitochondria in rats fed a
high carbohydrate diet and an increase in the number of mito-
chondria in those fed a LCKD compared to normal diet group.
Rats on LCKD had a remarkable tolerance to ischemia and a
faster recovery of cardiac function following reperfusion (Al-Zaid
et al., 2007). Transcriptional upregulation of key mediators of
mitochondrial oxidative phosphorylation by LCKD significantly
extended the lifespan of mice with Med30zg mutation (Krebs
et al., 2011). Typically, theMed30zg mutation causes a progressive
and selective decline in the transcription of genes necessary for
oxidative phosphorylation and mitochondrial integrity, eventu-
ally leading to cardiac failure. A ketogenic diet favorably affected
serum biomarkers for cardiovascular disease in normal-weight
men (Al-Zaid et al., 2007) and in obese diabetic subjects (Dashti
et al., 2007). Cardioprotective effects of β-OHB could be also
related to their ability to suppress oxidative stress via transcrip-
tional (Krebs et al., 2011; Shimazu et al., 2013) regulation of
key mediators of oxidative stress. The recent study from Eric
Verdin’s group (Shimazu et al., 2013) demonstrated that β-OHB
is an endogenous and specific inhibitor of class I histone deacety-
lases (HDACs). Inhibition of HDAC by β-OHB was correlated
with global changes in transcription, including that of the genes
encoding oxidative stress resistance factors Forkhead box O3a
(FOXO3a) and MT2. Consistent with increased FOXO3a and
MT2 activity, treatment of mice with β-OHB led to substan-
tial protection against oxidative stress. The anti-oxidant effect of
β-OHB could be also related to the ability of ketone bodies to
oxidize co-enzyme Q (Sato et al., 1995; Veech et al., 2001; Veech,
2004). The major source of mitochondrial free radicals is the half-
reduced semiquinone of co-enzyme Q (Chance et al., 1979). Q
semiquinine reacts directly withO2 to form the superoxide radical
O2−. By decreasing the reduced form of co-enzyme Q, the mito-
chondrial production of free radical can be decreased. In a second
action of ketone body metabolism, in addition to reducing the
mitochondrial NAD+/NADH redox couple, there is also a reduc-
tion of the cytoplasmic free NADP+/NADPH couple. This favors
the reduction of glutathione, which is near equilibrium through
the action of glutathione reductase (Krebs and Veech, 1969). This
is turn would favor the destruction of H2O2 by the glutathione
peroxidase reaction (Veech et al., 2001; Squires et al., 2003).
However, glutathione levels were unchanged during glutamate-
induced ROS generation in neurons while ketones inhibited ROS
generation by increasing NADH oxidation (Haynes et al., 2003).
While there are many studies which demonstrate that a keto-
genic diet results in the improvement of cardiovascular health
and significant weight loss, completely opposite results were also
reported. For example in an animal study by Wang et al. (2008),
rats were fed with LCKD or control diet for 2 weeks and isolated
hearts were subjected to normal perfusion in Langendorff mode,
with 30min global low flow ischemia (LFI) followed by 60min
reperfusion, or 60min LFI followed by 120min reperfusion. They
found that LCKD diet resulted in impaired left ventricular perfor-
mance during global LFI, reduced recovery of function following
LFI and reperfusion, and 10- to 20-fold increased injury as mea-
sured by lactate dehydrogenase release and histologic infarct area.
Serum FFA, glucose and lactate levels were not different between
diet groups, but LCKD did lead to a 2-fold increase in β-OHB
(from 0.3 to 0.6mM) and a 50% decrease in the fed-state insulin
level (from 34 to 15μU/ml) compared to control.
In addition, ketogenic diets can cause biochemical distur-
bances and cardiac dysfunction in certain vulnerable patients,
possibly due to latent defects in ketone body metabolism (Best
et al., 2000). In this case study, 20 patients on a ketogenic diet as a
treatment for partial seizures and refractory childhood epilepsy
were investigated. Prolonged QT interval [with corrected QT
(QTc) longer than 450ms] and cardiac chamber enlargement
were found in three pediatric patients (15%). There was a sig-
nificant correlation between prolonged QTc and both low serum
bicarbonate and high β-OHB levels suggesting that the levels of
acidosis or ketosis may be important factors in these cardiovas-
cular complications. However, it is important to emphasize that
in 17 patients who actually benefited from ketogenic diet (these
patients were weaned off anticonvulsants), the serum levels of
β-OHB ranged between 4.4 and 6.9mmol/L (Best et al., 2000).
In one patient presented with cardiovascular complications, the
serum level of β-OHB of 11.7mmol/L was detected on admission
to the hospital. This excessive elevation of β-OHB definitely can
play a role in the development of cardiovascular complications.
Cardiovascular disease is a well-known complication of diabetes
where levels of β-OHB could reach 25mMormore in poorly con-
trolled type 1 diabetes (Cahill and Veech, 2003). Agemay also play
a role, as younger children can have higher β-OHB levels. Some
epilepsy patients may have abnormal transcellular membrane
ion channels resulting in a predisposition to develop conduction
abnormalities as seen in those who develop long QT on cisapride,
tricyclics, or class I and III antiarrhythmics (Best et al., 2000).
One study revealed that β-OHB at high concentrations (10mM)
reduced L-type Ca2+ current in guinea pig ventricular myocytes
but only in the presence of the β–adrenergic agonist isoproterenol,
however it had no effect on L-type Ca2+ current under basal
conditions (Kurihara et al., 2012). Another study suggested that
the L-stereoisomer of β-OHB could block the transient outward
K+ current (Ito) in murine ventricular myocytes causing action
potential prolongation (Doepner et al., 1997) while D-β-OHB
had no effect. However, this study was later retracted and no other
studies are currently available demonstrating possible effects of
β-OHB on channel activity in cardiomyocytes. Moreover, hepatic
ketogenesis only produces D-β-OHB, which is the only form that
is a D-β-hydroxybutyrate dehydrogenase substrate, and thus, a
substrate for oxidation (Scofield et al., 1982). L-β-OHB is pos-
sibly formed during hydrolysis of the β-oxidation intermediate
L-β-OHB-CoA in cardiac mitochondria and does not circulate in
the blood (Scofield et al., 1982; Tsai et al., 2006). Interestingly,
only the heart contains significant amounts of L-stereoisomer of
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β-OHB (Tsai et al., 2006) but its physiological role is unclear.
It has been shown that only D-β-OHB was able to inhibit glu-
cose utilization in cardiomyocytes while L-stereoisomer had no
effect (Tsai et al., 2006). In a concentration of 5mM of D-β-OHB,
a maximum inhibition effect of 61% of control was found, but
L-β-OHB did not interfere with glucose utilization in concentra-
tions from 0.5 to 5mM. Additionally, when cells were in medium
containing L-β-OHB and 5mM of D-β-OHB, the reduced glu-
cose utilization caused by D-β-OHB gradually recovered with
increasing concentrations of L-β-OHB (Tsai et al., 2006).
Currently, very limited data is available on the role of ketone
body metabolism in HF. While a mild elevation of blood ketone
bodies occurs during congestive HF (Kupari et al., 1995; Lommi
et al., 1996, 1997), no changes in cardiac ketone body utilization
were detected in humans with advanced HF (Janardhan et al.,
2011). It remains unclear whether this elevation represents an
adaptivemechanism required tomaintain cell metabolism in con-
ditions of HF or actually contributes to the progression of disease.
It has been suggested that ketone bodies might be an impor-
tant fuel during persistent human atrial fibrillation (AF) (Mayr
et al., 2008). Proteomic and metabolic analysis of atrial tissue har-
vested during cardiac surgeries from patients with AF revealed
a 2-fold increase in SCOT expression, a mitochondrial matrix
enzyme required to activate ketones by transferring CoA from
succinyl-CoA to AcAc, the key reaction in ketolytic energy pro-
duction (see Figure 2). Consistent with the proteomic findings,
metabolomic analysis revealed a rise in the levels of β-OHB and
ketogenic amino acids, notably tyrosine, which forms AcAc and
fumarate during catabolism. Fumarate levels were markedly ele-
vated in persistent AF, and consequently the fumarate/succinate
ratio increased. The latter is often used as an indicator for the
redox state of the coenzyme Q couple (Sato et al., 1995), which
is the cofactor for the succinate dehydrogenase reaction and links
complex I and complex III of the respiratory chain via its redox
span. Both NADH dehydrogenase (complex I) and ubiquinol
cytochrome C reductase (complex III) were among the differ-
entially expressed proteins in the proteomic screen. Moreover,
animal studies have shown that administration of glucose plus
ketone bodies resulted in an increase in the fumarate/succinate
ratio similar to the observation in humans with AF (Sato et al.,
1995). Interestingly, that elevated myocardial energy expendi-
ture in patients with HF was associated with significant changes
in serum metabolomics profiles, especially the concentration of
β-OHB, acetone and succinate (Du et al., 2014). Elevated myocar-
dial energy expenditure correlates with reduced left ventricular
ejection fraction in HF, and has also been documented as an inde-
pendent predictor of cardiovascular mortality (Palmieri et al.,
2008). Again, it was not investigated whether this elevation in
ketone bodies and succinate was a result of adaptation during
cardiac remodeling in conditions of HF or represents a maladap-
tive mechanism contributing to the development of the disease.
Definitely, more studies are required to shed light on the role
of ketone bodies in cardiovascular diseases. Moreover, to avoid
the negative side effects of the ketogenic diets, absorbable ketone
body esters comprised of the mono ester of D-β-OHB and R-1,3-
butanediol were developed by Veech and colleagues (Clarke et al.,
2012a,b). It has been demonstrated that feeding ketone body
esters to rats lowers blood glucose and insulin, demonstrating that
ketosis actually increases insulin sensitivity (Veech, 2013, 2014).
It was suggested that the negative effects of LCKD were associ-
ated not with ketone bodies themselves but rather with enhanced
release of free fatty acids from the adipose tissue and the corre-
spondent increase in peroxisome proliferators-activated receptor
(PPAR) transcription factors with many undesirable effects like
development of the atherosclerosis as one example (Kersten et al.,
2000).
ROLES OF cPHB IN HEALTH AND DISEASE
Elevated levels of plasma β-OHB observed in HF and diabetes
could potentially lead to increased accumulation of cPHB. The
pioneering work of Dr. Rosetta Reusch from Michigan State
University demonstrated that cPHB could bind to a wide range
of proteins modifying the function of voltage-gated ion channels
and calcium ATPase pumps (see above and Reusch, 1989, 1992).
Dr. Reusch has further demonstrated the importance of cPHB to
medicine by showing that cPHB is present in a wide variety of
human tissues and also in atherosclerotic plaques (Reusch, 1989,
1992; Reusch et al., 1992; Seebach et al., 1994). However, during
digestion processes cPHB may become detached from proteins,
and its physical properties—water-insoluble, high intrinsic vis-
cosity, ability to make bilayers non-selectively permeant to ions,
sticky (forms multiple non-covalent bonds)—suggest that it may
be a factor in the development of some human and animal dis-
eases (Reusch, 1992). Reusch et al. (2003) compared cPHB levels
in plasma and tissues of streptozotocin diabetic rats with those in
healthy Sprague–Dawley rats. They found 3-to-8-fold increases
in cPHB levels in diabetic rats compared to the control animals
in the plasma and tissues affected by complications of diabetes—
kidney, eye, sciatic nerve, and aorta. These data strongly indicate
that cPHBmay be an important factor in the development of dia-
betes, and that plasma cPHB levels may serve as a marker for the
disease. Moreover, Norris et al. (2009) proposed that the high
intrinsic viscosity of cPHB may play a role in raising intraoc-
ular pressure leading to glaucoma. They suggested that cPHB,
adhering to filaments in the extracellular matrix, traps debris and
triggers aggregation of fibers. This reduces the size of the pores
and the flow of the aqueous humor through the meshwork, and
thereby raises intraocular pressure.
Using a crotonic acid detection test and cPHB antibodies,
Rosetta Reusch was first to demonstrate that cPHB is present
in human plasma mainly together with the low-density lipopro-
teins and with the carrier protein albumin (Reusch et al., 1992).
Reusch et al. (1992) determined cPHB levels in plasma of a ran-
dom group of 24 normal adults and found that concentrations
varied from 0.6 to 18.2mg/l, with a mean of 3.5mg/l. They fur-
ther determined that cPHB is carried in lipoprotein particles and
albumin—20 to 30% of cPHB is in VLDLs, intermediate den-
sity lipoproteins (IDL), and LDLs with most of the remaining
70–80% in albumin. Importantly, they found that cPHB con-
centrations in plasma correlated strongly with atherogenic lipid
profiles. Moreover, no cPHB was associated with HDL. cPHB
from ingested food may enter the circulation in the chylomi-
crons and VLDL similarly to cholesterol (Ramasamy, 2013;Welty,
2013). The amount of cPHB in the VLDL may be a function of
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diet, postprandial phase, and genetic factors. Since cPHB can-
not be extracted from VLDL with CHCl3, it is considered to
be tightly complexed to proteins. The presence of esterases or
depolymerases in VLDL is indicated by the lability of cPHB in
these particles (Reusch et al., 1992). As VLDL are converted to
IDL and then to LDL in the VLDL-IDL-LDL cascade (Ramasamy,
2013), cPHB may be degraded to β-OHB and/or transferred to
albumin which solubilizes cPHB and binds it irreversibly (Reusch
et al., 1992). Presumably the cPHB-laden albumin is taken to the
liver for disposal. cPHB which eludes these disposal mechanisms
remains in the LDL. It appears that cPHB accumulates in the
denser subgroup of LDL that is most atherogenic (Welty, 2013).
It is also noteworthy that cPHB in LDL is CHCl3-soluble, indi-
cating that it is no longer complexed to protein (Reusch et al.,
1992). This cPHB, like cholesterol, is likely carried within the
lipid core of the LDL particle, which is composed of triglycerides
and phospholipids (Reusch et al., 1992; Reusch, 2012). It is this
free polyester that may be harmful. As LDL travel through the
circulation, some cPHB may be deposited in the arteries and
act as a nucleus for the accumulation of cholesterol and other
lipids, proteins, salts, etc., thus enhancing atheroma formation
(Reusch, 2012). cPHB may also insert into cell membranes, mak-
ing them non-specifically permeable to ions. In fact the presence
of small amounts cPHB was demonstrated in mitochondria iso-
lated from healthy bovine hearts (Seebach et al., 1994). Studies
from Pavlov’s group (Elustondo et al., 2013a,b; Smithen et al.,
2013) addressed the potential role of cPHB in regulation of mito-
chondrial function. First, they revealed that endogenous cPHB
plays a role in mitochondrial Ca2+ uptake (Smithen et al., 2013).
Mitochondrial PHB depletion achieved by targeted expression of
bacterial PHB hydrolyzing enzyme (PhaZ7) significantly inhib-
ited mitochondrial Ca2+ uptake stimulated by ATP in intact
HepG2, U87 and HeLa cells or by elevated extramitochondrial
Ca2+in permeabilized cells. Furthermore, they (Elustondo et al.,
2013a,b) demonstrated that addition of synthetic fluorophore-
labeled cPHB (fluo-PHB) led to PHB accumulation specifically
in mitochondria of cultured HeLa cells. Accumulation of fluo-
PHB induced mitochondrial membrane potential depolarization
that was delayed by cyclosporin A, de-sensitizer of the mPTP.
Moreover, it was demonstrated that fluo-PHB addition caused
the transient increase in cytosolic Ca2+ concentration in human-
derived wild-type SH-SY5Y cells without any affect on mito-
chondrial Ca2+ concentration. However, addition of fluo-PHB
to the PINK1 knock-out SH-SY5Y cells which have an impaired
mitochondrial Ca2+ efflux due to the reduced activity of the
mitochondrial Ca2+/Na+ exchanger (Gandhi et al., 2009) led to
a significant and more sustainable accumulation of Ca2+ inside
mitochondria. These data indicate that similar to results obtained
in phospholipid bilayers of artificial vesicles (Seebach and Fritz,
1999), PHB can increase permeability of plasma and mitochon-
drial membrane to Ca2+ especially under certain pathological
conditions. The exact mechanisms of the increased permeability
for Ca2+ are unknown, however it has been proposed that PHB
can act as a natural Ca2+ ionophore (Elustondo et al., 2013a).
Consideration of PHB as a potential natural ionophore is partic-
ularly important in the light of the slow kinetics of mitochondrial
ion transport discussed in Kane and Pavlov (2013). Using simple
calculations, the authors concluded that the rates of ion trans-
port in intact mitochondria are an order of magnitude lower than
can be expected from the estimates based on electrophysiologi-
cal data obtained in swollen mitoplasts. Specifically: (1) based on
direct patch-clamp assays, the Ca2+ uniporter is expected to gen-
erate a current equivalent to ∼50 pA per single mitochondrion
(Kirichok et al., 2004), with some recent papers reporting even
higher values (Jean-Quartier et al., 2012; Bondarenko et al., 2013).
The estimated maximal uniporter current across the membrane
of the functional, intact organelle is expected to be only about
0.1 pA. Furthermore, the uniporter Ca2+ flux in the mitochon-
dria of intact cells is estimated to be in the order of 0.005 pA.
The presence of slow Ca2+ uptake system was in fact suggested
to maintain nearly normal animal developmental and physiolog-
ical function in mitochondrial Ca2+ uniporter knock-out mice
(Pan et al., 2013). Moreover, it should be noted that cPHB incor-
poration in membranes would also increase bilayer viscosity,
which may negatively influence the performance of membrane
proteins (Reusch, 2012, 2013). The fact that mitochondria with
highly negative membrane potential across the inner mitochon-
drial membrane ( =∼-180mV) can accumulate fluo-PHB,
which is a negatively charged polymer, suggests the existence of
an active transport system for PHB. Cyclosporin A sensitivity of
PHB-induced mitochondrial membrane depolarization suggests
the possible involvement of PHB in activation or regulation of
mPTP.
WHAT IS INORGANIC POLYPHOSPHATE?
polyP is a linear polymer of orthophosphate (Pi) residues linked
together by high-energy phosphoanhydride bonds as in ATP
(Figure 3A) (Kornberg et al., 1999). PolyP is present in all liv-
ing organisms ranging from bacteria to human, and possibly even
predating life of this planet (Brown and Kornberg, 2004). The
length of polyP chain can vary from just a few phosphates to
several thousands phosphate units long, depending on the organ-
ism and the tissue in which it is synthesized (Kornberg et al.,
1999; Brown and Kornberg, 2004, 2008). PolyP was extensively
studied in prokaryotes and unicellular eukaryotes by Kulaev’s
group in Russian Academy of Sciences (Kulaev et al., 1999a,b)
and by the Nobel Prize Laureate Arthur Kornberg at Stanford
University (Kornberg et al., 1999; Brown and Kornberg, 2008).
In prokaryotes, polyP is synthesized primarily by polyP kinase
1 (PPK1) via transferring the terminal phosphate from ATP
to the end of the growing polyP chain (Figure 3A), and this
reaction is fully reversible and may allow the bacteria to syn-
thesize ATP from stored polyP in times of starvation and envi-
ronmental stress (Kornberg et al., 1999; Brown and Kornberg,
2004, 2008). Null mutants of PPK1, with low polyP levels, are
deficient in survival: namely, they show deficient responses to
physical-chemical stresses and predation (Brown and Kornberg,
2004, 2008). Importantly, PPK1 is not the sole polyP-generating
enzyme in bacteria since null mutants of PPK1 which lack the
ability to produce long-chain polyP (Crooke et al., 1994) still
contained a membrane-bound short-chain polyP with 60–70
Pi residues (Castuma et al., 1995). Kornberg’s group was the
first to identify the presence of a new type of PPK (termed
DdPPK2, Figure 3A) in Dictyostelium discoideum slime mold
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FIGURE 3 | Inorganic polyphosphate structure, formation, and
utilization. (A) The upper panel shows the structure of inorganic
polyphosphate. The n represents the number of phosphate residues in the
polyphosphate chain. It could vary from ten to hundreds of units. The bottom
panel is a schematic representation of polyP formation by polyP-generating
enzymes in prokaryotes (left) and the putative polyP-generating enzymes in
mammalian cells (right). (B) Identified pathways and enzymes for polyP
utilization in prokaryotes are shown on the left. Mammalian enzymes which
resemble the function of polyP-utilizing enzymes in prokaryotes are shown
on the right (see text for more details).
(Gomez-Garcia and Kornberg, 2004). Analysis of the single
43-kDa band yielded the remarkable result that the enzyme,
DdPPK2, is likely a complex of three actin-related proteins: Arp1,
Arp2, and an unreported Arpx that are similar to muscle actins in
size and properties. The enzymatic activity of DdPPK2 is highly
unusual: (i) synthesis of polyP by DdPPK2 is blocked by actin
inhibitors; (ii) this particular Arp complex is an enzyme that can
polymerize into an actin-like filament concurrent with its synthe-
sis of a polyP chain in a fully reversible reaction (Spudich, 2004).
However, most bacteria synthesize polyP by unknown mecha-
nisms since recent genome screenings through the genome search
engine BLAST revealed that PPK1 and PPK2 are present together
in less than half of bacterial taxa and that a third of taxa have
neither enzyme (Whitehead et al., 2014).
So far, no PPK1 homolog has been identified in higher-
order eukaryotes even though it is structurally similar to phos-
pholipase D (Zhu et al., 2005) and, therefore, PPK1 exhibits
potential as a novel target for chemotherapy that would affect
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both virulence and susceptibility to antibacterial compounds
(Brown and Kornberg, 2008). Moreover, it has been demon-
strated that plasma membrane Ca2+-ATPase from human ery-
throcytes may function as a polyphosphate kinase, i.e., it exhibits
ATP-polyphosphate transferase and polyphosphate-ADP trans-
ferase activities (Reusch et al., 1997). The mitochondrial F1F0-
ATP synthase can also contribute to polyP generation (see below
and Pavlov et al., 2010; Seidlmayer et al., 2012a for details). Two
bacterial enzymes [the second PPK (PPK2) and PolyP–AMP–
phosphotransferases (PAP)] use polyP as a substrate. PPK2 actu-
ally resembles mammalian thymidylate kinase (Whitehead et al.,
2013). PAP uses polyP as a substrate to phosphorylate AMP to
ADP, an immediate precursor of ATP. PolyP is degraded by both
endopolyphosphatases (PPNs) and exopolyphosphatases (PPXs)
(Figure 3B). In mammalians, a long-chain endopolyphosphatase
was purified from rat and bovine brain (Kumble and Kornberg,
1996), a human metastasis regulator protein H-prune was identi-
fied as a short-chain specific exopolyphosphatase (Tammenkoski
et al., 2008), and mammalian intestinal alkaline phosphatase
was characterized as a very active exopolyphosphatase (Lorenz
and Schroder, 2001). In addition, 41% homology has been
found between yeast exopolyphosphatase PP1 gene product and
human acid sphingomyelinase-like phosphodiesterase (Duan,
2006; Kulakovskaya and Kulaev, 2013). In the colon, this enzyme
may play anti-proliferative and anti-inflammatory roles via
ceramide generation, reducing the lysophosphatidic acid forma-
tion, and inactivating the platelet-activating factor and mutations
in its gene have been found in cancer cells of the intestines (Duan,
2006). Interestingly, the human protein H-prune exhibits 91%
homology with the sequences of yeast exopolyphosphatase PPX1
(Kulakovskaya and Kulaev, 2013). Furthermore, in some prokary-
otes [such as Micrococcus luteus, Corynebacterium ammoniagenes
(Fillipovich et al., 2000), Micrococcus flavus and Mycobacterium
tuberculosis (Kawai et al., 2000)] NAD kinase catalyzes phospho-
rylation of NAD using both ATP and polyP as phosphoryl donors
(Figure 3B) while E. Coli NAD kinase is not able to use polyP
(Kawai et al., 2001). Remarkably, human mitochondrial NAD
kinase has been recently identified to have the ability to utilize
both ATP and polyP as the phosphoryl donor (Ohashi et al.,
2012). Neglected and long regarded a molecular fossil, polyP
has a variety of significant functions in bacteria such as a (i)
source of energy (Kulaev, 1979; Wood and Clark, 1988; Kulaev
et al., 1999b), (ii) phosphate reservoir (Kulaev et al., 1999b), (iii)
donor for sugar and adenylate kinases (Bonting et al., 1991; Hsieh
et al., 1993; Phillips et al., 1993), (iv) chelator for divalent cations
(Van Veen et al., 1993), (v) buffer against alkaline stress (Pick
et al., 1990), (vi) regulator of development (Gezelius et al., 1973),
and (vii) structural element in competence for DNA entry and
transformation (Reusch and Sadoff, 1988). Even though most
of polyP research has been performed in microorganisms, the
presence of polyP has been demonstrated in many mammalian
tissues (Figure 4) such as rodent liver, kidney, lungs, brain, and
heart (Kumble and Kornberg, 1995), rabbit heart (Seidlmayer
et al., 2012a,b), as well as in human granulocytes (Cowling
and Birnboim, 1994), platelets (Smith et al., 2006; Smith and
Morrissey, 2008a; Morrissey et al., 2012), and fibroblasts (Pisoni
and Lindley, 1992). In striking contrast to microorganisms where
polyP is present in millimolar (50–120mM) concentrations, lev-
els of 25–200μM (it terms of Pi residues) were found in vast
majority of mammalian tissues (Kumble and Kornberg, 1995;
Seidlmayer et al., 2012b). The exceptions are platelets and mast
cells which contain millimolar concentrations of polyP in elec-
tron dense granules (see below). Intracellular distribution of
polyP also varies with relatively higher levels of polyP detected
in nuclei and plasma membranes isolated from rat liver com-
pared to the cytosol, mitochondria, and microsome fractions
(Kumble and Kornberg, 1995). Our studies performed on mito-
chondria isolated from rabbit hearts detected the presence of
∼200μM (280 pmol/mg of protein) short-chain polyP with an
average chain length of 25 orthophosphates (Figure 5A modified
from Seidlmayer et al., 2012b). Because polyP is found in small
amounts in mammalian cells, it does not serve as phosphate or
energy storage (Figure 4) but is implicated in cell proliferation
(Wang et al., 2003), angiogenesis (Han et al., 2007), apopto-
sis (Hernandez-Ruiz et al., 2006), osteoblast function (Kawazoe
et al., 2004), blood clotting and inflammation (Smith et al., 2006,
2010; Smith and Morrissey, 2008a,b; Muller et al., 2009; Mutch
et al., 2010a,b; Choi et al., 2011; Morrissey et al., 2012), cell
bioenergetics (Pavlov et al., 2010; Seidlmayer et al., 2012a), ion
channel function (Abramov et al., 2007; Kim and Cavanaugh,
2007; Zakharian et al., 2009; Seidlmayer et al., 2012b) and nuclear
transcription (Jimenez-Nunez et al., 2012). These new discoveries
compelled us to take a fresh look at this natural polymer that has
been ignored in biochemistry textbooks for a long time.
PolyP METABOLISM IN MAMMALIAN CELLS AND ROLE OF
MITOCHONDRIA
At present very little is known about the molecular details of
polyP metabolism in mammalian cells, however it has been
demonstrated that newly identified human mitochondrial NAD
kinase utilizes not only ATP but also polyP as the phosphoryl
donor (Ohashi et al., 2012). It has been postulated for many
years that only a subset of bacterial or archaeal NAD kinases
exhibit high polyP-dependent NAD kinase activity, while eukary-
otic NAD kinases do not (Kawai and Murata, 2008). NAD
kinase is the sole NADP+-biosynthetic enzyme known to cat-
alyze phosphorylation of NAD+ to yield NADP+ and plays
a role in the defense against mitochondrial oxidative stress
(Pollak et al., 2007). To date no mammalian polyP producing
enzymes have been identified, however it has been demon-
strated that polyP production in mammalian cells depends on
the metabolic state of the mitochondria (Pavlov et al., 2010;
Seidlmayer et al., 2012a). Experiments performed on isolated
rat liver mitochondria, cultured intact cells (astrocytes, HEK
293) and rabbit cardiomyocytes demonstrated that levels of
polyP were increased by substrates of the mitochondrial respi-
ratory chain and in turn reduced by mitochondrial inhibitor
(rotenone) or respiratory chain uncouplers [carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) or carbonylcyanide-
m-chlorophenylhydrazone (CCCP)]. Oligomycin, an inhibitor
of mitochondrial F1F0-ATP-synthase, blocked the production
of poly P. These data suggest that in mammalian mitochon-
drial polyP production is closely related to the activity of the
oligomycin-dependent F1F0-ATP synthase. However, whether or
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FIGURE 4 | Inorganic polyphosphate sources and functions in mammalian cells. Shown is a schematic representation of the described pathways of polyP
occurrence and functions in mammalian cells.
not F1F0-ATP synthase is polyP generating enzyme remains to be
validated. Furthermore, enzymatic depletion of polyP from cells
achieved by overexpression of the mitochondria-targeted yeast
polyphosphatase (MTS-GFP-scPPX1) significantly impaired res-
piratory chain activity (Abramov et al., 2007) and decreased
the rate of ATP production which indicates the existence of a
feedback mechanism between polyP production and cell energy
metabolism (Pavlov et al., 2010). These data are in agreement
with earlier studies, where the turnover of polyP demonstrated
dependence on the metabolic activity of cells examined (Kumble
and Kornberg, 1995). Addition of radioactive 32Pi to cultured cells
led to rapid (within minutes to 1 h) phosphate incorporation into
polyP in PC12 cells while less metabolically active cells such as
embryonic kidney cells and T-cells (Jurkat) showed a significantly
slower or no polyP synthesis at all (Kumble and Kornberg, 1995).
Furthermore, lysis of cells resulted in a loss of polyP synthetic
activity. The authors postulated that polyP synthesis is an energy-
dependent process which requires participation of mitochondria
(Kumble and Kornberg, 1995; Kornberg et al., 1999).
We investigated the kinetics of mitochondrial polyP
metabolism (Seidlmayer et al., 2012a) in intact ventricular
cardiomyocytes isolated from control rabbits and animals with
HF combined aortic insufficiency and stenosis model (Dedkova
et al., 2013). The relative changes in levels of polyP were measured
using the fluorescent probe DAPI, with a protocol optimized
specifically for polyP detection (Aschar-Sobbi et al., 2008;
Seidlmayer et al., 2012b). As demonstrated in Figure 5B addition
of membrane permeable methyl-succinate—the substrate of the
complex II of the mitochondrial respiratory chain—resulted in
an increase in DAPI fluorescence by 36 ± 8% (n = 8), indicating
significant stimulation of the production of mitochondrial polyP
(Figures 5B,C). On the other hand uncoupling of respiration
with FCCP decreased DAPI fluorescence by 29 ± 4% (n = 8)
presumably due to the stimulation of polyP hydrolysis. This
indicates that polyP concentration in cardiac myocytes is variable
and depends on levels of energy substrates and the degree of
coupling of the mitochondrial respiratory chain. Moreover, we
found that polyP metabolism was significantly suppressed in
mitochondria of HF myocytes. Addition of methyl-succinate
caused only a moderate increase in DAPI fluorescence (16 ± 2%,
n = 10) (Figures 5B,C). Also, the basal polyP levels were signifi-
cantly lower in conditions of HF (224 ± 21 a.u. in HF vs. 453 ±
80 in control) (Figure 5D). This observation raises the intrigu-
ing possibility that similarly to bacteria, polyP production in
mammalian cells is directly linked to changes in cell metabolism
and environment and that diminished polyP synthesis observed
in HF myocytes results from the complex remodeling processes
during cardiac hypertrophy and HF. A recent study (Gray et al.,
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FIGURE 5 | Mitochondrial polyP concentration is highly variable in
healthy and heart failure cardiomyocytes and depends on respiratory
chain activity. (A) The upper panel image demonstrates polyP detection in
freshly isolated rabbit ventricular myocytes using DAPI as a sensor for polyP
(λex = 408 nm, λem = 552–617 nm). The bottom panel shows the average
amount of polyP in rabbit heart mitochondria (left) and gel images of polyP
standard and polyP sample from isolated rabbit mitochondria (right). (B)
Original recordings of DAPI fluorescence changes in intact cardiac myocytes
stimulated with 5mM methyl-succinate followed by 5μM FCCP from control
(black) and failing myocytes (red). DAPI fluorescence represents changes in
polyP concentration. (C) Average values of basal DAPI fluorescence in control
(black) and heart failure (red) myocytes. (D) Average values of maximal DAPI
fluorescence after methyl-succinate addition in control (black) and heart
failure (red) cells. Modified with permission from Seidlmayer et al. (2012a,b).
2014) determined that in E. Coli bacteria polyP acts as an efficient
protein chaperon which stabilizes proteins in vivo, diminishes
the need for other chaperone systems to survive proteotoxic
stress (temperature, low pH, oxidants) conditions, and protects
a wide variety of proteins against stress-induced unfolding and
aggregation. It has been demonstrated that wild type E. coli
stains generated significant amounts of polyP in response to
oxidative stress. This polyP accumulation played a critical role
in E. coli defense against stress since PPK mutant stains which
are not able to produce polyP displayed decreased survival and
elevated levels of protein aggregates compared to wild-type
strains in response to oxidant or heat stress. PPK mutants
showed increased activation of heat shock response, consistent
with them suffering from more protein damage upon a similar
stress compared to the wild-type. Importantly, we reported a
significant increase in reactive oxygen species (ROS) generation
and cell death in polyP-depleted ventricular myocytes exposed
to simulated ischemia-reperfusion (Seidlmayer et al., 2013)
suggesting a protective role of polyP in conditions associated with
increased oxidative stress. Furthermore, cell-free experiments
revealed that polyP inhibits the aggregation of chemically and
heat-denaturated luciferase and citrate synthase, previously
established protein chaperon substrates (Gray et al., 2014). PolyP
maintained these substrates in a refolding competent state,
which required the assistance of the canonical ATP-dependent 70
kilodalton heat shock protein (Hsp70)/DnaK machine. Utilizing
standard in vitro chaperone assays, it was demonstrated that the
presence of 1μM polyP was sufficient to significantly reduce
thermal luciferase aggregation while 100μM polyP completely
prevented aggregate formation. Millimolar concentrations,
however, were required to inhibit oxidant or heat-induced
aggregation of citrate synthase. Moreover, long-chain polyP
polymers (with 130–300 phosphate residues) were more effective
as chaperones compared to short chain polymers (∼14 phosphate
residues). These experiments provide evidence that polyP exerts
chaperone activity in concentration- and length-dependent
manner and that this activity varies with different substrates.
The finding that polyP has stress-protective chaperone activities
that resemble the activity of small heat shock proteins is very
exciting, however additional research is required to determine
the mechanisms of protein aggregation prevention by polyP and
the protein targets of polyP in mammalian cells.
INORGANIC PolyP AND ACTIVATION OF THE
MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mPTP)
One of the most intriguing and least intuitive roles of polyP
is its involvement in membrane ion transport. In 1988 Reusch
and Sadoff, using bilayer techniques, demonstrated that geneti-
cally competent E. coli bacteria contain an ion channel formed
by a complex of polyP and PHB (Reusch and Sadoff, 1988).
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The channel formed by polyP/Ca2+/PHB interaction was selec-
tive for cations with a preference for Ca2+(Reusch and Sadoff,
1988; Reusch et al., 1995). Later a similar polyP/Ca2+/PHB
channel was isolated from rat liver mitochondria (Pavlov et al.,
2005b). Interestingly, in addition to the cation selective con-
ductance state this mitochondrial complex also demonstrated
a high-conductance, weakly-selective, voltage-dependent state.
These properties in many ways reflected the behavior of the
mPTP as seen in patch-clamp studies of native mitochondrial
membranes (Kinnally et al., 1991; Szabo and Zoratti, 1991).
Interestingly, the polyP/Ca2+/PHB channel of bacterial origin
also has this high conductance state (Pavlov et al., 2005a) and
the transition of the channel into a high conductance state would
most likely be deleterious for bacterial organisms, raising the
question whether most of the time the bacterial channel is either
closed or is in the low conductance cationic state. The differ-
ent bacterial conductance states are reminiscent of conductance
states proposed for the mPTP (Ichas et al., 1997; Huser et al.,
1998; Ichas and Mazat, 1998). The parallels between bacteria
and mitochondria also suggest that similar cationic channels
may play a role in normal mitochondrial function. In sup-
port of such notion the polyP/Ca2+/PHB complex has been
detected in various eukaryotic organisms and cellular compart-
ments suggesting a potential physiological role (Reusch, 1989).
Currently, the direct test whether a polyP/Ca2+/PHB complex
indeed forms the pore part of the mPTP in intact mitochon-
dria remains an experimental challenge. Nonetheless, the idea
that the presence of polyP in intact mitochondria is an essential
condition for mPTP opening remains an intriguing hypothesis.
Indeed, it was shown that mitochondria of cultured cells with
reduced levels of polyP are more resistant toward Ca2+-induced
mPTP opening (Abramov et al., 2007). In our work performed
in rabbit ventricular cardiomyocytes we demonstrated that polyP
depletion with MTS-GFP-scPPX1 overexpression effectively pre-
vented Ca2+-induced mPTP opening (Figures 6A,B modified
from Seidlmayer et al., 2012b). In contrast to non-excitable
cells (Abramov et al., 2007), polyP depletion did not affect the
ability of mitochondria to accumulate Ca2+, however signifi-
cantly increased the resistance of cardiac mitochondria to open
mPTP (Figure 6C) and prevented Ca2+-induced loss of mito-
chondrial membrane potential (Figure 6D) indicating that polyP
is a potent activator of Ca2+-induced mPTP. On the other hand,
when mPTP activity was monitored in conditions of simulated
ischemia-reperfusion accompanied by massive ROS generation,
polyP depletion was not able to prevent mPTP opening and
cell death during reperfusion. In fact, as we demonstrated ear-
lier (Seidlmayer et al., 2013), ROS generation and cell death was
significantly increased under conditions of ischemia-reperfusion
in polyP-depleted cells. We found different modes in mPTP
activity during ischemia and reperfusion, and that these modes
were affected differently by polyP. In agreement with our data
obtained on permeabilized cells (Seidlmayer et al., 2012b), polyP
depletion prevented Ca2+-induced low conductance mPTPmode
observed during ischemia, however it did not affect ROS-induced
mPTP opening in the high-conductance mode during reper-
fusion. These exciting findings indicate that polyP has a dual
effect on mPTP activity—promoting the transient opening of
Ca2+-induced mPTP opening which can prevent mitochondria
from Ca2+ overload. On the other hand, polyP was required for
protection against oxidative stress-induced mPTP opening and
cell death. It is unclear at this point, whether this effect of polyP
was related to the recently discovered chaperone activity of polyP
or the direct effect of polyP on mPTP. Recent data suggest that
dimers of the of F1F0-ATP synthase can form channels with char-
acteristics similar to the mPTP (Giorgio et al., 2013), however
the molecular details of channel formation by F1F0-ATP syn-
thase remain unclear. Particular attention has been brought to
the subunit c of the F1F0-ATP synthase as a potential compo-
nent of the mPTP (Azarashvili et al., 2014; Bonora et al., 2013).
Interestingly, an interaction of polyP/Ca2+/PHB complex with
subunit c of F1F0-ATP synthase was reported back in 2005 (Pavlov
et al., 2005b), and therefore it is possible that polyP could pro-
vide a fine tuning of mPTP regulation or actually mediate Ca2+
transfer through mPTP.
PolyP IS A LINK BETWEEN HUMAN GASTROINTESTINAL
TRACT BACTERIA, β -OHB AND CARDIOVASCULAR HEALTH
It has recently been discovered that human gastrointestinal tract
bacteria (probiotics) produce polyP, and that polyP is respon-
sible for probiotic actions that protect the intestinal epithelia
from oxidant stress and improve epithelial injury due to excess
inflammation (Segawa et al., 2011). It has been shown that polyP
specifically binds to integrin β1, and inhibition of integrins or
p38 MAPK pathway eliminates the protective effect of polyP on
intestinal epithelia (Segawa et al., 2011). P38 MAPK is a class
of mitogen-activated protein kinases responsive to stress stim-
uli, such as cytokines, ultraviolet irradiation, heat shock and
osmotic shock, and is involved in cell differentiation and apop-
tosis. Indeed, protective effect of polyP was associated with its
ability to induce expression of the cytoprotective heat shock pro-
tein 27 (Hsp27) in these cells (Segawa et al., 2011) and to decrease
staurosporine-induced apoptosis as evidenced by the inhibition
of caspase-9 and caspase-3 activation. Althogether, these results
suggest that polyP develops a robust intestinal barrier function
through interaction with integrin β1, followed by the p38 path-
way activation. Intriguingly, recent studies (Lam et al., 2012; Gan
et al., 2014) demonstrated that probiotic administration attenu-
ates myocardial infarction following ischemia-reperfusion injury
andmyocardial hypertrophy andHF followingmyocardial infarc-
tion in the rat. Lam and coworkers (Lam et al., 2012) provided the
first evidence that probiotics may be cardioprotective by showing
that administration of a commercially-available beverage con-
taining the probiotic Lactobacillus plantarum 299 v 24 h before
subjecting rats to 30min of cardiac ischemia and 2 h reperfusion,
produced a 27% reduction in infarct size and improved reperfu-
sion by 35%. In the study of Gan et al. (2014), rats were subjected
to 6 weeks of sustained coronary artery occlusion and admin-
istered the probiotic Lactobacillus rhamnosus GR-1 or placebo.
They found that animals administered GR-1 exhibited a signif-
icant attenuation of left ventricular hypertrophy and improved
hemodynamic parameters. Serial echocardiography revealed sig-
nificantly improved left ventricular parameters throughout the
6 week follow-up period including a marked preservation of
left ventricular ejection fraction as well as fractional shortening.
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FIGURE 6 | PolyP depletion prevents opening of the permeability
transition pore induced by mitochondrial Ca2+ overload. (A) The upper
panel shows co-localization of GFP-PPX signal with mitochondria. TMRM was
used as a mitochondrial signal and the degree of overlay is presented in
shades of yellow in the merged image. The bottom panel shows the
decrease in DAPI fluorescence in polyP-depleted cells. (B) Fluorescence
spectrum of DAPI (5μM) loaded myocytes expressing control GFP (black),
PPX (red), and control GFP cells not loaded with DAPI (gray). (C) Original
recordings of mPTP opening using calcein red release from mitochondria of
permeabilized control (black) and polyP-depleted (PPX expressing, red)
myocytes. After permeabilization cells were exposed to 2μM Ca2+ and
10μg/ml alamethicin was added at the end of the experiment to achieve the
maximal calcein red release from mitochondria. (D) Original recordings of
mitochondrial membrane potential (m) with the voltage-sensitive dye
TMRM in permeabilized cells upon elevation of the [Ca2+]em from 0.1 to
2μM, and subsequent addition of 1μM FCCP in control (black) and
polyP-depleted (PPX expressing, red) myocytes. Modified with permission
from Seidlmayer et al. (2012b).
Beneficial effects of GR-1 were still evident in those animals in
which GR-1 was withdrawn at 4 weeks suggesting persistence
of the GR-1 effects following cessation of therapy. Investigation
of mechanisms showed a significant increase in the leptin to
adiponectin plasma concentration ratio in rats subjected to coro-
nary ligation which was abrogated by GR-1. Metabonomic analy-
sis showed differences between sham control and coronary artery
ligated hearts particularly with respect to preservation of myocar-
dial taurine levels. These studies suggest that gut microbiota can
modulate cardiovascular disease possibly due to alterations in the
production of gut-derived hormones which exert cardiovascular
effects. Specifically, both studies detected a significant decrease in
leptin production in probiotic-treated animals. PolyP levels were
not measured in these studies, however, it is plausible to speculate
that polyP produced by gut microbiota could also exerts a car-
dioprotective role for the host organism. Interestingly, germ-free
mice which were born and raised in sterile gnotobiotic isolators,
had a significantly reduced heart weight (Crawford et al., 2009)
compared to those of normally colonized mice. Metabolic and
physiological studies revealed that functional parameters (heart
rate, hydraulic work, mitochondrial morphology, number, and
respiration, plus ketone body, fatty acid, and glucose oxidation)
of the hearts of germ-free mice were relatively normal in fed
conditions. However, a significant decrease in hepatic ketogen-
esis and levels of circulating β-OHB was detected under fasting
conditions in germ-free mice with a compensatory increase in
cardiac glucose oxidation (Crawford et al., 2009). The reduc-
tion in heart size and alterations of myocardial metabolism were
reversed in germ-free mice maintained on a ketogenic diet or fol-
lowing microbial colonization (Crawford et al., 2009). Altogether,
the data demonstrate the existence of a link between gut micro-
biota and cardiovascular health, however the exact roles of polyP
and β-OHB in cardiovascular health and disease remain to be
determined. It is intriguing to speculate that polyP produced by
gut microbiota can modulate signaling cascades and ketone body
metabolism. Importantly, mammalian intestinal alkaline phos-
phatase has been described as a very active exopolyphosphatase
(Lorenz and Schroder, 2001), which can split long-chain polyP
produced by gut microbiota into short-chain polyP and phos-
phate. The short-chain polyP could be efficiently absorbed in
human intestinal tract and excreted in the urine (Karp et al.,
2012). A recent study (Karp et al., 2012) compared the effect
of polyP and phosphate supplementation in healthy women
19–31 years of age and revealed that both monophosphate and
polyP induced an increase in serum parathyroid hormone and
serum/urine phosphate levels, while only polyP led to a significant
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decrease in urinary Ca2+ levels. This decrease in Ca2+ levels most
likely was due to enhanced Ca2+ binding to polyP in intestine
and decreased Ca2+ absorption (Zemel and Linkswiler, 1981). In
mammals, circulating inorganic phosphate and polyP (complexes
with Ca2+) serve to support extracellular mineralization, which
appears to furthermore depend on the concerted expression
of collagen type 1 and tissue-non-specific alkaline phosphatase
(Murshed et al., 2005). To control mineralization and cellular
delivery, extracellular phosphate levels and total body phos-
phate content are tightly regulated by a number of hormones,
including parathyroid hormone, 1,25-dihydroxy-vitamin D, and
fibroblast growth factor-23 (FGF23), and serum phosphate feeds
back to regulate these factors in an endocrine fashion (Civitelli
and Ziambaras, 2011): high phosphate increases the secretion of
parathyroid hormone and FGF23, while low phosphate stimulates
the synthesis of 1,25-dihydroxy-vitamin D. Hypophosphatemia
leads to demineralization of the skeleton (osteomalacia), whereas
hyperphosphatemia is an important risk factor for the develop-
ment of vascular calcifications (Rutsch et al., 2011). Interestingly,
it has been shown recently that polyP actually stimulates FGF23
expression through activation of fibroblast growth factor receptor
(Sun et al., 2012), and promotes bone mineralization (Hacchou
et al., 2007). Moreover, while polyP of different chain length
(short, medium, and long) stimulated FGF23 expression, polyP
with long chains actually led to the increased lactic acid accu-
mulation and cell death (Sun et al., 2012). Furthermore, high
levels of circulating FGF23 are linked to the increased incidents
of pathological cardiovascular events (Arnlov et al., 2013).
ROLES OF PolyP AND β-OHB IN CELL
PROLIFERATION—IMPLICATIONS FOR CANCER BIOLOGY
It has been demonstrated that addition of polyP to human plasma
cells produced an unexpected inhibition of immunoglobulin
secretion and stimulation of apoptosis. PolyP induced apoptosis
specifically in human plasma cells, myeloma (malignant plasma
cells) cell lines, primary myeloma cells, and B lymphoid cell lines
(Hernandez-Ruiz et al., 2006). Normal B cells, T cells, total blood
mononuclear cells, and non-lymphoid cell lines were not affected
by polyP. In the U266 myeloma cell line, polyP induced external-
ization of phosphatidylserine, activation of caspase-3, and arrest
of the cell cycle. The protective effects of interleukin-6 did not
overcome the polyP-induced apoptosis. This study, however, used
very high (3–6mM) concentrations of polyP with various chain
lengths (25, 45, and 75 Pi residues), and detected that in these
concentrations polyP effectively inhibited immunoglobulin secre-
tion, initiated apoptosis and reduced cell survival of the U266
myeloma cell line. Since total peripheral bloodmononuclear cells,
T cells, B cells, and non-lymphoid cell lines were not affected, it
was suggested that polyP could potentially be useful in the design
of new antimyeloma drugs. Also, polyP could contribute in part
to maintaining low levels of plasma cells in blood circulation
(Jimenez-Nunez et al., 2012).
Another study (Han et al., 2007) demonstrated that polyP
effectively blocked in vivo pulmonary metastasis of B16BL6 cells
by suppression of neovascularization, whereas it did not affect
proliferation or adhesion to extracellular matrix proteins. PolyP
not only inhibited bFGF (basic fibroblast growth factor)-induced
proliferation and ERK (extracellular-signal-regulated kinase)/p38
MAPK (mitogen-activated protein kinase) activation of human
endothelial cells, but also blocked the binding of bFGF to its
cognate cell surface receptor. Furthermore, polyP inhibited bFGF-
induced in vitro and in vivo angiogenesis, suggesting that polyP
possesses an anti-angiogenic activity. Since neovascularization is
essential for tumor metastasis, these findings indicate that polyP
has an in vivo anti-metastatic activity via its anti-angiogenic
activity.
Interestingly, ketogenic diet lowered the serum ratio of
IGF/IGF-binding protein 3 in mice with positive effects on
metabolic syndrome and cancer risk (Freedland et al., 2008). Also,
ketogenic diet (and elevated β–OHB) increased AMPK in mice,
inhibiting the mTOR/Akt signaling pathway (McDaniel et al.,
2011). However, polyP was also found to stimulate mTOR signal-
ing and possibly cancer growth (Wang et al., 2003). In this study,
polyP depletion achieved by overexpression of yeast exopolyphos-
phatase PPX1 gene inhibited proliferation of the human breast
carcinoma cell line MCF-7 via mTOR signaling cascade. These
conflicting results definitely should stimulate further research to
determine the exact roles of polyP and β–OHB in cell growth
and cancer biology. Recently, human metastasis regulator protein
H-prune was identified as a short-chain specific polyP hydrolase
(Tammenkoski et al., 2008). Long-chain polyP (>25 phosphate
residues) were converted more slowly, whereas pyrophosphate
and nucleoside triphosphates were not hydrolyzed. Notably, the
exopolyphosphatase activity of H-prune was suppressed by long-
chain polyphosphates and pyrophosphate, which could be poten-
tial physiological regulators. Clearly, the chain length of polymer
determines the physiological role of polyP making it either a
friend or foe.
ROLE OF PolyP IN BONE TISSUE DEVELOPMENT AND
MINERALIZATION
The vertebrate skeleton is predominately composed of bone,
a mineralized tissue that consists of type-1 collagen, non-
collagenous proteins and a calcium phosphate mineral known
as apatite (Omelon et al., 2009). Unlike invertebrate skeletons
or protective shells, the vertebrate skeleton is continually rebuilt,
repaired and resorbed during growth, normal remodeling, and
recovery from traumas and diseases. Even though the role of
polyP in the modulation of bone mineralization was suggested
nearly 15 years ago (Leyhausen et al., 1998), only recently consid-
erable advances were made in the study of polyP contribution to
bone tissue development (Kawazoe et al., 2004; Hacchou et al.,
2007; Omelon et al., 2009; Morimoto et al., 2010; Usui et al.,
2010). It has been shown that polyP is present abundantly in
normal human osteobalsts, at bone-resorbing osteoclastic sites,
in the proliferating and hypertrophic zone chondrocytes, in the
hypertrophic zone matrix, and in unmineralized osteoid (Shiba
et al., 2003; Kawazoe et al., 2008). Moreover, polyP enhanced
alkaline phosphatase activity and expression of osteopontin and
osteocalcin genes in MC3T3-E1 osteoblastic cells suggesting that
polyP promotes calcification in these cells (Kawazoe et al., 2004).
Interestingly, polyP was detected in electron-dense Ca2+-rich
granules localized at sites of bone resorption (Omelon et al.,
2009). The size of these dense granules was larger (in the range
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of a few thousand angstroms) than previously reported for mito-
chondrial electron-dense clusters in mineralizing osteoid (rang-
ing from 400 to 1000 angstroms) (Landis et al., 1977) The authors
(Omelon et al., 2009) put together a hypothesis that apatite min-
eral dissolution in the osteoclast resorption zone increases the
concentrations of free Pi and Ca2+. The mitochondria may scav-
enge the Pi and condense it into polyP that may also sequester
Ca2+. Amorphous granules containing total concentrations of
Ca2+ and Pi higher than the saturation of apatite are formed
and may be transported out of the osteoclast. The granules may
be transported to or produced within the osteoblasts that build
new bone. The osteoblasts may embed the granules in osteoid
(new, unmineralized bone). The reaction of these granules with
alkaline phosphatase (present at the membrane of osteoblasts)
cleaves Pi from polyP and would increase the free Pi concentra-
tion and release any sequestered Ca2+. The increase in free Ca2+
and Pi could exceed the saturation for apatite and result in apatite
mineral formation. Most recently (Tsutsumi et al., 2014), it was
demonstrated that polyP promotes MC3T3-E1 cell maturation
from a resting state to an active blastic cell phase which implies
that polyP can be an effective material for bone regeneration. The
enzyme responsible for polyP synthesis in bone tissue cells has
not been identified and the signal molecules determining separate
stages of this process are unknown. Fascinating, in vivo exper-
iments demonstrated that artificial introduction of polyP into
the bone growth or regeneration zone accelerates these processes
(Grynpas et al., 2002; Pilliar et al., 2007; Shanjani et al., 2007; Doi
et al., 2014). The finding that polyP induces osteoblastic differen-
tiation and bone mineralization creates a basis for development
of novel polyP-containing drugs for bone disease treatment and
new polyP-containing materials for bone substitution.
ROLE OF PolyP IN BLOOD COAGULATION AND
INFLAMMATION
It has been known formany years that polyP accumulates inmany
infectious microorganisms (Kornberg et al., 1999) and therefore
could play a significant role in inflammation. Microbial polyP
(with chain length of more than 500 Pi residues), which is highly
pro-coagulant, may function in host responses to pathogens
(Chuang et al., 2013). Of particular interest to hematology, it
has been demonstrated that polyP is a major component of
dense granules of human platelets (Ruiz et al., 2004) and aci-
docalcisomes of mast cells (Moreno-Sanchez et al., 2012), where
millimolar levels (in terms of Pi residues) of short chain polyP
(∼70–75 phosphate units in platelets and 60 phosphate units in
mast cells) were detected. Like acidocalcisomes, human platelets
dense granules are spherical, acidic, electron-dense, and contain
large amounts of calcium and potassium in addition to polyP
(Ruiz et al., 2004). Both human platelets and mast cells secrete
polyP upon activation which indicates that polyP could be an
important mediator of their pro-inflammatory and pro-coaguant
activities. Indeed, studies from Morrissey’s lab and others have
shown that polyP is a potent modulator of the blood clotting
cascade, acting as a pro-hemostatic, pro-thrombotic and pro-
inflammatory agent depending on its polymer size and location
(Smith et al., 2010). PolyP may represent at least one of the long-
sought patho-physiologic activators of the contact pathway of
blood clotting, and its actions may also help to explain previously
unexplained abilities of activated platelets to enhance plasma clot-
ting reactions. Targeting polyP with phosphatases interfered with
pro-coagulant activity of activated platelets and blocked platelet-
induced thrombosis in mice (Muller et al., 2009). Addition
of polyP restored defective plasma clotting of Hermansky–
Pudlak Syndrome patients, who lack platelet polyP (Muller
et al., 2009). Remarkably, both Hermansky–Pudlak (HPS) and
Chediak–Higashi (CHS) syndromes have in common dense gran-
ule deficiency and bleeding tendency (Salles et al., 2008), which is
congruent with the presence of poly P in dense granules (Ruiz
et al., 2004) and its role in blood clotting (Smith et al., 2006). The
data identify polyP as a new class of mediator having fundamental
roles in platelet-driven pro-inflammatory and pro-coagulant dis-
orders. PolyP acts via several points in the clotting cascade: (i)
it triggers clotting via the contact pathway (Smith et al., 2006,
2010; Muller et al., 2009), (ii) it accelerates factor V activation
(Smith et al., 2006), (iii) it enhances fibrin clot structure (Smith
and Morrissey, 2008b; Mutch et al., 2010a), and (iv) it accelerates
factor XI back-activation by thrombin (Mutch et al., 2010b; Choi
et al., 2011). It was demonstrated that very long polymers (with
more than 500 Pi residues, such as those present in microorgan-
isms) were required for optimal activation of the contact pathway,
while shorter polymers (with ∼100 Pi residues, similar to the
polymer lengths released by platelets) were sufficient to acceler-
ate factor V activation and abrogate the anticoagulant function of
the tissue factor pathway inhibitor. Optimal enhancement of fib-
rin clot turbidity by polyP required polyP with more than 250 Pi
residues. Therefore, polyphosphate of the size secreted by platelets
is very efficient at accelerating blood clotting reactions but is less
efficient at initiating them or at modulating clot structure (Smith
et al., 2010). PolyP may prove useful as a hemostatic agent to
control bleeding, and conversely, polyP antagonists might be ben-
eficial as anti-thrombotic/anti-inflammatory agents with reduced
bleeding side effects. Several polyphosphate inhibitors have been
identified recently and their effectiveness was tested in vitro andin
vivo (Smith et al., 2012). Polyphosphate inhibitors were anti-
thrombotic in mouse models of venous and arterial thrombosis
and blocked the inflammatory effect of polyphosphate injected
intra-dermally in mice. This provides proof of principle for
polyphosphate inhibitors as anti-thrombotic/anti-inflammatory
agents in vitro and in vivo, with a novel mode of action compared
with conventional anticoagulants (Smith et al., 2012). However,
the detailed molecular mechanisms by which polyP modulates
blood clotting reactions still remain to be elucidated (Morrissey,
2012).
PolyP REGULATES INNATE IMMUNITY BY MODULATING
iNOS EXPRESSION IN MACROPHAGES– SIGNALING ROLES
OF PolyP
It has been proposed recently that endogenous polyP may serve as
an intercellular signaling molecule in innate immunity (Harada
et al., 2013). As we discussed above, both platelets and mast
cells store polyP in their granules and secrete it into the extra-
cellular space when the cells are activated (Ruiz et al., 2004;
Moreno-Sanchez et al., 2012). Moreover, it has been shown that
parasites such as Trypanosoma cruzi (T. cruzi) contain polyP
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within molar levels in acidocalcisomes which is essential for the
parasite to resist the stressful conditions in the host and to main-
tain a persistent infection (Galizzi et al., 2013). Interestingly,
infection with T. cruzi leads to the development of chronic
Chagas heart disease characterized by autonomic nervous system
derangements, microvascular disturbances, parasite-dependent
myocardial infection, and immune-mediated myocardial injury
(Marin-Neto et al., 2007). Despite nearly one century of research,
the pathogenesis of chronic Chagas cardiomyopathy is incom-
pletely understood (Marin-Neto et al., 2007). Tightly packed
polyP may be released into the extracellular space and affect the
function of macrophages, thereby serving as an immune modu-
lator. Indeed, the recent study (Harada et al., 2013) demonstrated
that polyP suppressed inducible nitric oxide synthase (iNOS)
expression and nitric oxide (NO) release induced by lipopolysac-
charide (LPS), a cell wall component of Gram-negative bacteria,
in mouse peritoneal macrophages. In contrast, polyP did not
affect the LPS-induced release of TNF, another inflammatory
mediator. Using polyP of various chain lengths (14, 60, and 130
Pi residues) it was demonstrated that polyP with longer chains
(130 Pi residues) was more potent than those with shorter chains
in suppressing LPS-induced iNOS expression. It has been shown
that polyP suppressed LPS-induced iNOS expression by down-
regulating the level of mRNA expression, however the detailed
mechanisms are currently unknown. LPS-induced extracellular
Ca2+ influx enhances iNOS expression in macrophages (Kim
et al., 2004; Zhou et al., 2006). PolyP, a negatively charged polyan-
ion, may bind with extracellular Ca2+, inhibit LPS-induced Ca2+
influx, and result in a decreased expression of iNOS mRNA
(Harada et al., 2013). On the other hand, extracellular polyP has
been recently reported to modulate or activate receptors on the
plasma membrane, such as the FGF, integrin, and P2Y1 receptors
(Shiba et al., 2003; Segawa et al., 2011; Holmstrom et al., 2013).
Potentially, polyP may regulate iNOS expression via modulation
of these receptors.
CONCLUSIONS
The main objective of this review was to emphasize the impor-
tance of ketone body β-OHB, its natural polymer PHB, and
inorganic polyP in cardiovascular physiology and other diseases.
While physicians were always taught that elevation in β-OHB lev-
els is undesired, recent studies indicate that a mild elevation in
β-OHB levels could be actually beneficial in certain physiologi-
cal situations, and can modulate the important signaling cascades
involved in cell growth, proliferation and defense against oxida-
tive stress. Two ancient polymers, PHB and polyP, have proved
to be involved in regulation of protein channels in plasma mem-
brane and mitochondria, and should not be discarded as “relics”
from Prebiotic times.
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